An Extensive Comprehension of Forced Degradation Studies of New Drug Substances and Products
Main Article Content
Forced degradation tests are a method used in the pharmaceutical industry to assess the stability of medication samples. Stress examination of degradation products is beneficial in determining the pathways of degradation as well as designing and testing appropriate analytical techniques. Forced degradation experiments reveal chemical behavior of the molecule, which aids in formulation & package creation. According to the studies, the majority of researchers and reviewers claim to use ICH recommendations, Q1A-Q1F, for the degradation analysis and impurity profiling of drug substances & drug products. A variety of spectroscopic and chromatographic techniques like as UV spectroscopy, RP- HPLC, Gas Chromatography, and others may be used for regular analysis of pharmacological compounds and products. Forced degradation studies of medicinal compounds and products have found a significant application for hyphenated approaches. The current research also provides significant insights into the stability indicating assay techniques and their importance in determining medication stability. The study also discusses the role of excipients in the deterioration of pharmaceuticals.
ICH guidelines, Q1A (R2) (1994): Stability Testing of New Drug Substances and Products (revision 2), International Conference on Harmonization.
Reynolds DW, Facchine KL, Mullaney JF (2002). Available guidance and best practices for conducting forced degradation studies. Pharm. Technol., 26: 48-56.
Brummer H (2011). How to approach a forced degradation study. Life Sci. Technol. Bull. 31:1-4.
FDA Guidance for Industry, INDs for Phase II and III Studies—Chemistry, Manufacturing, and Controls Information, Food and Drug Administration.
FDA Guidance for Industry, INDs for Phase 2 and 3 Studies of Drugs, Including Specified Therapeutic Biotechnology-Derived Products, Draft Guidance, Food and Drug Administration.
Kats M (2005). Forced degradation studies: regulatory considerations and implementation. BioPharm Int., 18: 1-7.
Szepesi G (1989) Selection of high-performance liquid chromatographic methods in pharmaceutical analysis. Method validation J. Chromatogr. 464: 265-278.
Carr GP, Wahlich JC (1990) A practical approach to method validation in pharmaceutical analysis. J. Pharm. Biomed. Anal. 86: 613-618.
Jenke DR (1996). Chromatographic method validation: a review of common practices and procedures. J Liq Chrom Relat Tech. 19: 719-736.
ICH, Final Guidance on Stability Testing of Biotechnological/Biological Products Availability, International Conference on Harmonization.
ICH Guidance for Industry, Q1B: Photo stability Testing of New Drug Substances and Product, International Conference on Harmonization.
Maheswaran R (2012). FDA perspectives: scientific considerations of forced degradation studies in ANDA submissions. Pharm. Technol. 36: 73-80.
Klick S, Pim GM, Waterval J. (2005). Toward a generic approach for stress testing of drug substances and drug products. Pharm. Technol. 29: 48-66.
FDA Guidance for Industry, Analytical Procedures and Methods Validation: Chemistry, Manufacturing, and Controls Documentation, Draft Guidance, Food and Drug Administration.
CDER, Reviewer Guidance: Validation of Chromatographic Methods, Centre for Drug Evaluation and Research.
ICH Guidance for Industry, Q2B: Validation of Analytical Procedures: Methodology, International Conference on Harmonization.
Ngwa G (2010). Forced degradation studies as an integral part of HPLC stability indicating method development. Drug Deliv. Technol. 10: 56-59.
Banker GS, Rhodes CT (2002). Modern Pharmaceutics, 4th ed. Marcel Dekker, Inc., New York.
Bakshi M, Singh S (2002). Development of validated stability-indicating assay methods—critical review. J. Pharm. Biomed. Anal. 28: 1011-1040.
Singh S, Bakshi M (2000). Guidance on conduct of stress tests to determine inherent stability of drugs. Pharm. Technol. 24: 1-14.
Venkataraman S, Manasa M (2018). Forced degradation studies: Regulatory guidance, characterization of drugs, and their degradation products - a review. Drug Invention Today. 10: 137- 146.
Alsante KM, Ando A, Brown R (2007). The role of degradant profiling in active pharmaceutical ingredients and drug products. Adv. Drug Deliv. Rev. 59: 29-37.
Gupta A, Yadav JS, Rawat S (2011). Method development and hydrolytic degradation study of Doxofylline by RP HPLC and LC–MS/MS. Asian J. Pharm. Anal. 1: 14-18.
Boccardi G, Baertschi SW (2005). Oxidative susceptibility testing. Pharmaceutical Stress Testing-Predicting Drug Degradation. Taylor and Francis, New York. 220.
Ahuja S, Alsante KM (2003). Handbook of Isolation and Characterization of Impurities in Pharmaceutical. Academics Press, New York.
Baertschi SW, Thatcher SR, Piechocki J (2006). Sample presentation for photo stability studies: problems and solutions, Pharmaceutical Photostability and Stabilization Technology. Taylor & Francis, New York.
M. Allwood M, Plane J (1996). The wavelength-dependent degradation of vitamin A exposed to ultraviolet radiation. Int. J. Pharm., 31: 1-7.
Ahuja S, Scypinski S (2001). Handbook of Modern Pharmaceutical Analysis. 1st ed. Academic Press, New York.
Qiu F, Norwood DL (2007). Identification of pharmaceutical impurities. J. Liq. Chromatogr. Relat. Technol., 30: 877-935.
Trabelsi H, Hassen IE, Bouabdallah S (2005). Stability indicating LC method for determination of Pipamperone. J. Pharm. Biomed. Anal. 39: 914-919.
Dolan JW (2002). Stability-indicating assays: LC troubleshooting LC-GC N. Am. Pharm. Rev. 20: 346-349.
Smela JW (2005). Regulatory considerations for stability indicating analytical methods in drug substance and drug product testing. Am. Pharm. Rev. 8: 51-54.
Annapurna MM, Mohapatro C, Narendra A (2012). Stability-indicating liquid chromatographic method for the determination of Letrozole in pharmaceutical formulation. J. Pharm. Anal., 2: 298-305.
Synder LR, Glajch JL, Kirkland JJ (1997). Practical HPLC Method Development. 2nd ed., Wiley, New York.
Riddhiben MP, Piyushbhai MP, Natubhai MP (2011). Stability indicating HPLC method development—a review. Int. Res. J. Pharm., 2: 79-87.
ICH, Q6A: Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances, International Conference on Harmonization, Geneva.
Ali NW, Abbas SS, Zaazaa HE (2012). Validated stability indicating methods for determination of Nitazoxanide in presence of its degradation products. J. Pharm. Anal. 2: 105-116.
Bichsel VE, Curcio V, Gassmann R (1996). Requirements for the quality control of chemically synthesized peptides and biotechnologically produced proteins. Pharm. Acta Helv. 71: 439-446.
EMA Guideline on the Limits of Genotoxic Impurities, Committee for Medical Products for Human Use (CHMP).
ICH, Q3A (R2): Impurities in New Drug Substances, International Conference on Harmonization, Geneva.
ICH, Q3B (R2): Impurities in New Drug Products, International Conference on Harmonization, Geneva.
FDA Guidance for Industry, ANDAs: Impurities in Drug Substances (draft), Food and Drug Administration, Rockville, MD.
FDA Guidance for Industry, ANDAs: Impurities in Drug Products (draft), Food and Drug Administration, Rockville, MD.
ICH Guidance for Industry, Q6B: Specifications: Test Procedures and Acceptance Criteria for Bio-technological/Biological Products, International Conference on Harmonization.
Singh R, Rehman Z (2012). Current trends in forced degradation study for pharmaceutical product development. J. Pharm. Educ. Res. 3: 54-63.
Blessy M, Patel RD, Prajapati PN, Agrawal YK (2014). Development of forced degradation and stability indicating studies of drugs- A review. J. Pharm. Ana. 4: 159- 165.
Bansal G, Singh M, Jindal K, Singh S (2008). LC and LC- MS study on Establishment of Degradation Pathway of Glipizide under Forced Decomposition Conditions. Journal of Chrom. Sci. 46:510- 517.
Banker and Rhodes (2002). Stability Studies. 4th edition. Marcel Dekker Inc. New York.
Rajan V, Patil S (2018). Reversed Phase High Performance Liquid Chromatography Method for Determination of Assay and Forced Degradation Study of Apremilast from Active Pharmaceutical Dosage Form. J. Chem. Pharm. 10: 139-144.
Murali D, Rao P (2018). Stability Indicating RP-HPLC Method for the Simultaneous Estimation of Imipenem and Cilastatin in Injection Formulations. World J. Pharm. Res. 8: 898-913.
Reddy B, Radhakrishnan P, Alam I, Kiran P (2019). A Validated Stability Indicating RP-HPLC Method Development for Anticancer Drug Enzalutamide in Bulk and Pharmaceuticals. Int. J. Pharm. Sci. Drug Res. 11: 85-90.
Bhole R, Zombade T, Bonde C, Zambare Y (2019). Identification and Characterization of Degradation Products by Using MS-MS Studies for Developed and Validated Stability Indicating HPTLC Method for Estimation of Nintedanib Esylate in Pharmaceutical Dosage Form. Eurasian J. Anal. Chem. 14: 60-70.
Prakash V, Suresh J, Konari S (2018). RP-HPLC Forced Degradation Studies of Aztreonam in Pharmaceutical Dosage Form. Pharm Methods. 9: 40-44.
El-ghobashy M, Yehia A, Helmy A, Nadia Y (2018). Forced degradation of Gliquidone and development of validated stability-indicating HPLC and TLC methods. Braz. J. Pharm. Sci. 54: 3- 6.